| NSC | Compound | Enrichment | Correlation |
|---|---|---|---|
| NSC 745455 | Null | 0.00770426557728506 | 0.22484997 |
| NSC 748707 | Null | 0.00770426557728506 | 0.015908058 |
| NSC 752464 | methyl 2-((S,3Z)-6-((E)-1-hydroxy-3-phenylallylidene)-5-oxocyclohex-3-enyl)acetate | 0.00770426557728506 | 0.2295291 |
| NSC 757113 | METHOTREXATE(+/-) | 0.00770426557728506 | 0.39628438 |
| NSC 163424 | 4-Quinazolinamine, 2-[2-(1-pyrrolidinylazo)phenyl]- | 0.00803384002766641 | 0.20333546 |
| NSC 173552 | L-Aspartic acid, N-[4-[[(2-amino-4-hydroxy-6-quinazolinyl)methyl]amino]benzoyl]-, monohydrate | 0.00803384002766641 | 0.44099054 |
| NSC 339579 | 7H-Pyrrolo[3,2-f]quinazoline-2,4-diamine, 7-[(3-nitrophenyl)methyl]-, monoacetate | 0.00803384002766641 | 0.45464648 |
| NSC 351521 | Ethanesulfonic acid, 2-hydroxy-, compd. with 6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d] pyrimidine-2,4-diamine (1:1) | 0.00803384002766641 | 0.37328465 |
| NSC 614887 | Platinum, (1,2-cyclohexanediamine-N,N')bis (4-morpholinepropanesulfonato-O)-, (SP-4-2) | 0.00803384002766641 | 0.25153007 |
| NSC 637411 | Null | 0.00803384002766641 | 0.23792089 |